Novartis: Just What The Doctor Ordered
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
GlobalData on MSN20h
Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Bangladesh Sangbad Sangstha (BSS)4d
Writ seeking probe Novartis share transfer removed from cause list
DHAKA, Feb 10, 2025 (BSS) - The writ petition regarding the transfer of shares of Novartis Bangladesh Limited has been ...
Novartis buys Blackstone's Anthos for up to $3.1bln
Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture ...
Novartis agrees to acquire Anthos for up to $3.1 billion
Swiss pharmaceutical giant Novartis said on Tuesday it has agreed to acquire biopharma firm Anthos Therapeutics ...
The Business Standard4d
Writ against Tk230cr Novartis shares transfer to be placed another HC bench: Petitioner
Following the court’s decision, writ petitioner Advocate Iktandar Hossain Hawlader told the media that he would move to another High Court bench for a hearing ...
Switzerland’s pharmaceutical industry faces new threat as Trump eyes tariffs
U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...
Fintel on MSN1d
UBS Downgrades Novartis AG - Depositary Receipt () (NVS)
Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...